One shot to prevent cervical cancer: zambia tests cheaper HPV vaccine
NCT ID NCT07256912
First seen Jan 05, 2026 · Last updated May 25, 2026 · Updated 22 times
Summary
This study will compare how well a single dose of the CERVAVAC HPV vaccine works versus a single dose of the Gardasil vaccine in 1,266 girls, boys, and young women in Zambia. Participants aged 9 to 20 will receive one shot and be followed for 24 months to measure their immune response. The goal is to see if CERVAVAC is as effective as Gardasil at protecting against HPV, which causes cervical cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER PREVENTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chipata and Matero First Level Hospitals
Lusaka, Zambia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.